{"id":745212,"date":"2015-04-23T00:00:00","date_gmt":"2015-04-23T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/"},"modified":"2025-11-07T01:25:14","modified_gmt":"2025-11-07T06:25:14","slug":"mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/","title":{"rendered":"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection"},"content":{"rendered":"<p class=\"bwalignc\">       Data Sets Include Treatment-Na\u00efve, Treatment-Experienced and HIV        Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6        Infection     <\/p>\n<p class=\"bwalignc\">       Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food        and Drug Administration (FDA) in First Half of 2015     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentations of data from the company\u2019s<br \/>\n      ongoing <i>C-EDGE<\/i> pivotal Phase 3 clinical trial program evaluating<br \/>\n      the investigational once-daily tablet grazoprevir\/elbasvir (100mg\/50mg)<br \/>\n      in patients with or without cirrhosis who are infected with chronic<br \/>\n      hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6).<sup>1<\/sup><br \/>\n      Patients in both the HCV infected, treatment-na\u00efve (<i>C-EDGE TN<\/i>),<br \/>\n      and HIV\/HCV co-infected, treatment-na\u00efve (<i>C-EDGE CO-INFXN<\/i>) trials<br \/>\n      treated for 12 weeks achieved rates of sustained virologic response 12<br \/>\n      weeks after the completion of treatment (SVR12) of 95 percent (299\/316<br \/>\n      and 207\/218, respectively). In addition, HCV infected,<br \/>\n      treatment-experienced patients (<i>C-EDGE TE<\/i>) treated with or<br \/>\n      without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent<br \/>\n      (98\/104) and 92 percent (97\/105), respectively, and those treated for 16<br \/>\n      weeks achieved SVR12 rates of 97 percent (103\/106) and 92 percent<br \/>\n      (97\/105), respectively. These data were presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Filc-congress.eu%2F&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=The+International+Liver+CongressTM+2015&amp;index=1&amp;md5=8fe8629519690173f979d801b4b43d66\" rel=\"nofollow\">The<br \/>\n      International Liver Congress<sup>TM <\/sup>2015<\/a> \u2013 the 50<sup>th<\/sup><br \/>\n      annual congress of the European Association for the Study of the Liver<br \/>\n      (Abstract #G07, E-Poster P0886 and E-Poster P0887). A paper detailing<br \/>\n      the findings of <i>C-EDGE TN<\/i> was published online in the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fannals.org&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=Annals+of+Internal+Medicine&amp;index=2&amp;md5=bcc743784203b2e054ab07a38221817e\" rel=\"nofollow\"><i>Annals<br \/>\n      of Internal Medicine<\/i><\/a> today.\n    <\/p>\n<p>\n      \u201cPatients with co-morbidities and varying treatment experiences<br \/>\n      represent important segments of the chronic hepatitis C population in<br \/>\n      need of additional innovative treatment options,\u201d said Dr. Eric Lawitz,<br \/>\n      vice president, scientific and research development, The Texas Liver<br \/>\n      Institute and clinical professor of medicine, The University of Texas<br \/>\n      Health Science Center, San Antonio. \u201cThese findings are important<br \/>\n      because they demonstrate that a single pill of grazoprevir\/elbasvir<br \/>\n      taken once-daily achieved consistently high rates of SVR12 in the<br \/>\n      patient populations studied.\u201d\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\" colspan=\"13\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\" colspan=\"13\">\n          <b>Summary of SVR12 findings: <i>C-EDGE TN<\/i>, <i>C-EDGE CO-INFXN<\/i>,<br \/>\n          <i>C-EDGE TE<\/i><\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\" rowspan=\"2\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwpadb1 bwvertalignm bwalignl\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <i><b>C-EDGE <\/b><\/i><br \/><i><b>TN<\/b><\/i>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <i><b>C-EDGE<\/b><\/i><br \/><i><b>CO-INFXN<\/b><\/i>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\" colspan=\"7\">\n          <i><b>C-EDGE TE<\/b><\/i>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Without<\/b><br \/><b>RBV<\/b><br \/><b>(n=316)<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Without <\/b><br \/><b>RBV<\/b><br \/><b>(n=218)<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Without <\/b><br \/><b>RBV <\/b><br \/><b>(n=105)<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>With<\/b><br \/><b>RBV<\/b><br \/><b>(n=104)<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Without <\/b><br \/><b>RBV <\/b><br \/><b>(n=105)<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>With<\/b><br \/><b>RBV<\/b><br \/><b>(n=106)<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          <b>Duration<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>12 weeks<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>12 weeks<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>12 weeks<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>12 weeks<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>16 weeks<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>16 weeks<\/b>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>All Patients:<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          95%\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          95%\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          92%\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          92%\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          97%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          <b>SVR12<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (299\/316)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (207\/218)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (97\/105)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (98\/104)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (97\/105)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (103\/106)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Cirrhotic<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          97%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          89%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          89%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          92%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (68\/70)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (35\/35)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (33\/37)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (31\/35)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (35\/38)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (37\/37)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Non-cirrhotic<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          97%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          93%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          96%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (231\/246)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (172\/183)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (64\/68)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (67\/69)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (62\/67)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (66\/69)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Genotype 1a<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          92%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          90%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          93%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          94%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          95%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (144\/157)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (136\/144)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (55\/61)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (56\/60)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (45\/48)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (55\/58)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Genotype 1b or<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>other Genotype<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          99%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          96%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          97%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          96%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignl bwsinglebottom\">\n          <b>1<\/b>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (129\/131)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (43\/45)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (35\/35)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (28\/29)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (46\/48)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (38\/38)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Genotype 4<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n<p class=\"bwcellpmargin\">\n            96%\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          78%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          93%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          60%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (18\/18)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            (27\/28)\n          <\/p>\n<\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (7\/9)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (14\/15)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (3\/5)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (8\/8)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl\">\n          <b>Genotype 6<\/b>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          80%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          75%\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc\">\n          100%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (8\/10)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (1\/1)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          N\/A\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          N\/A\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (3\/4)\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          (2\/2)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      \u201cAt Merck, we continue to build upon our clinical experience using<br \/>\n      grazoprevir\/elbasvir across diverse populations of patients infected<br \/>\n      with chronic hepatitis C virus,\u201d said Dr. Eliav Barr, vice president,<br \/>\n      infectious diseases, Merck Research Laboratories. \u201cWe remain on track to<br \/>\n      submit a New Drug Application with the U.S. Food and Drug Administration<br \/>\n      in the first half of 2015.\u201d\n    <\/p>\n<p>\n      <span class=\"bwuline\"><i>C-EDGE TN Overview and Additional Findings<\/i><\/span>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105467&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=C-EDGE+TN&amp;index=3&amp;md5=b7c94eb4172721210d3864b2f87f47c8\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      TN<\/i><\/a> is a randomized, blinded, placebo-controlled trial evaluating<br \/>\n      the efficacy and safety of grazoprevir\/elbasvir in treatment-na\u00efve<br \/>\n      patients with or without cirrhosis infected with chronic HCV GT1, 4 or 6<br \/>\n      who received therapy for 12 weeks. Patients were randomized to an<br \/>\n      immediate treatment group that received grazoprevir\/elbasvir for 12<br \/>\n      weeks or to a deferred treatment group that received placebo for 12<br \/>\n      weeks, were followed for an additional four weeks, and then received<br \/>\n      open label grazoprevir\/elbasvir for the next 12 weeks. The primary<br \/>\n      efficacy analysis included those patients who received immediate<br \/>\n      treatment with grazoprevir\/elbasvir or placebo. Of the 316 patients who<br \/>\n      received immediate treatment with grazoprevir\/elbasvir, 50 percent were<br \/>\n      infected with GT1a, 42 percent with GT1b, six percent with GT4 and three<br \/>\n      percent with GT6. Overall, 22 percent of patients had liver cirrhosis.\n    <\/p>\n<p>\n      In this study, virologic failure occurred in 13 patients (4%) in the<br \/>\n      immediate treatment group, including one virologic breakthrough and 12<br \/>\n      virologic relapses. Serious adverse events occurred in nine (3%) and<br \/>\n      three (3%) patients in the immediate treatment and corresponding placebo<br \/>\n      arms, respectively; none were considered drug-related. The most common<br \/>\n      adverse events reported (greater than 5% incidence) in the immediate<br \/>\n      treatment and corresponding placebo groups, were headache (17%, 18%),<br \/>\n      fatigue (16%, 17%), nausea (9%, 8%) and arthralgia (6%, 6%),<br \/>\n      respectively.\n    <\/p>\n<p>\n      <span class=\"bwuline\"><i>C-EDGE CO-INFXN Overview and Additional Findings<\/i><\/span>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105662&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=C-EDGE+CO-INFXN&amp;index=4&amp;md5=eb113894fc1604c2f716a5dc328dfb9e\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      CO-INFXN<\/i><\/a> is an open label, single-arm study evaluating the<br \/>\n      efficacy and safety of grazoprevir\/elbasvir in treatment-na\u00efve patients<br \/>\n      with or without cirrhosis infected with chronic HCV GT1, 4 or 6 and HIV<br \/>\n      who received therapy for 12 weeks. Of the 218 patients enrolled in the<br \/>\n      trial, 66 percent were infected with HCV GT1a, 21 percent with GT1b or<br \/>\n      other GT1, 13 percent with GT4, and one percent with GT6. Overall, 16<br \/>\n      percent of patients had liver cirrhosis.\n    <\/p>\n<p>\n      In this study, virologic failure occurred in seven patients (3%),<br \/>\n      including six virologic relapses and one reinfection. There were no<br \/>\n      reported drug-related serious adverse events. The most common (greater<br \/>\n      than 5% incidence) adverse events reported were fatigue (13%), headache<br \/>\n      (12%) and nausea (9%).\n    <\/p>\n<p>\n      <span class=\"bwuline\"><i>C-EDGE TE Overview and Additional Findings<\/i><\/span>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02105701&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=C-EDGE+TE&amp;index=5&amp;md5=8974217487bbb98970f0787872c368c2\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      TE<\/i><\/a> is a randomized study evaluating the efficacy and safety of<br \/>\n      once-daily grazoprevir\/elbasvir with or without twice-daily RBV in<br \/>\n      treatment-experienced (prior null response, partial response or relapse<br \/>\n      with peg-interferon\/RBV) patients with or without cirrhosis infected<br \/>\n      with chronic HCV GT1, 4 or 6 who received therapy for 12 weeks or 16<br \/>\n      weeks.\n    <\/p>\n<p>\n      <span class=\"bwuline\">12 week arms<\/span>\n    <\/p>\n<p>\n      Of the 209 patients randomized to the 12 week arms, 105 patients<br \/>\n      received grazoprevir\/elbasvir only and 104 patients<br \/>\n      received&nbsp;grazoprevir\/elbasvir plus RBV. Patients in the<br \/>\n      grazoprevir\/elbasvir only arm comprised 58&nbsp;percent GT1a, 33 percent GT1b<br \/>\n      or other GT1 and nine percent GT4. Overall, 35 percent had liver<br \/>\n      cirrhosis. Among the 104 patients receiving grazoprevir\/elbasvir plus<br \/>\n      RBV, 58 percent were infected with chronic HCV GT1a, 28 percent GT1b or<br \/>\n      other GT1, and 14 percent GT4. Overall, 34 percent had liver cirrhosis.\n    <\/p>\n<p>\n      In the grazoprevir\/elbasvir only and grazoprevir\/elbasvir plus RBV arms,<br \/>\n      six patients in each arm (6%) were reported to have virologic relapse.<br \/>\n      No patients were reported to have virologic breakthrough or rebound.<br \/>\n      Serious adverse events were reported in four patients in the<br \/>\n      grazoprevir\/elbasvir only arm (4%) and three patients in the<br \/>\n      grazoprevir\/elbasvir plus RBV arm (3%). The most common (greater than<br \/>\n      10% incidence) adverse events reported in the grazoprevir\/elbasvir and<br \/>\n      grazoprevir\/elbasvir plus RBV arms, respectively, were fatigue (19%,<br \/>\n      27%), headache (21%, 20%) and nausea (9%, 14%).\n    <\/p>\n<p>\n      <span class=\"bwuline\">16 week arms<\/span>\n    <\/p>\n<p>\n      Of the 211 patients enrolled in the 16 week arms, 105 patients received<br \/>\n      grazoprevir\/elbasvir only and 106 patients received grazoprevir\/elbasvir<br \/>\n      plus RBV. In the grazoprevir\/elbasvir only arm, 46&nbsp;percent were infected<br \/>\n      with chronic HCV GT1a, 46 percent with GT1b or other GT1, five percent<br \/>\n      with GT4 and four percent with GT6. Overall, 36 percent of patients had<br \/>\n      liver cirrhosis. Among those in the grazoprevir\/elbasvir plus RBV arm,<br \/>\n      55 percent were infected with chronic HCV GT1a, 36 percent with GT1b or<br \/>\n      other GT1, eight percent with GT4, and two percent with GT6. Overall, 35<br \/>\n      percent had liver cirrhosis.\n    <\/p>\n<p>\n      Among the patients receiving grazoprevir\/elbasvir only, three patients<br \/>\n      (3%) were reported to have virologic breakthrough or rebound and four<br \/>\n      patients (4%) were reported to have virologic relapse. No virologic<br \/>\n      failures occurred in patients receiving grazoprevir\/elbasvir plus RBV.<br \/>\n      Serious adverse events were reported in three patients in the<br \/>\n      grazoprevir\/elbasvir only arm (3%) and four patients in the<br \/>\n      grazoprevir\/elbasvir plus RBV arm (4%). The most common (greater than<br \/>\n      10% incidence) adverse events reported in the grazoprevir\/elbasvir and<br \/>\n      grazoprevir\/elbasvir plus RBV arms, respectively, were fatigue (16%,<br \/>\n      30%), headache (19%, 19%) and nausea (4%,17%).\n    <\/p>\n<p>\n      <b>About the <i>C-EDGE<\/i> Program<\/b>\n    <\/p>\n<p>\n      <i>C-EDGE <\/i>is the Phase 3 clinical development program for Merck\u2019s<br \/>\n      investigational HCV treatment grazoprevir\/elbasvir comprising five<br \/>\n      studies with more than 1,700 patients across more than 25 countries.<br \/>\n      These studies are evaluating grazoprevir\/elbasvir in multiple genotypes<br \/>\n      (GT1, 4 and 6) and diverse patient populations, including<br \/>\n      difficult-to-treat patients such as: treatment-experienced, patients<br \/>\n      with cirrhosis, HIV\/HCV co-infection, advanced chronic kidney disease,<br \/>\n      inherited blood disorders, and those receiving opiate substitution<br \/>\n      therapies.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      health care solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=42308a60d8e0d5b5b07ed3feaf09013d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=19af5fbc243277ff389ceb0fd1d41a40\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=35aea8df748d399edbc67f71d03ece4b\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=df590d633c567a2ec7da555c9a885efb\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of Merck\u2019s management and are subject<br \/>\n      to significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise except as required by applicable law. Additional factors that<br \/>\n      could cause results to differ materially from those described in the<br \/>\n      forward-looking statements can be found in Merck\u2019s 2014 Annual Report on<br \/>\n      Form 10-K and the company\u2019s other filings with the Securities and<br \/>\n      Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51086217&amp;newsitemid=20150423006879&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=0b9dd21daae2ffa83201417b23cbcd92\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Grazoprevir is an HCV NS3\/4A protease inhibitor and<br \/>\n      elbasvir is an HCV NS5A replication complex inhibitor\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150423006879r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li&nbsp;, 908-246-5701<br \/>or<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investors:<br \/>Joe Romanelli,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of data from the company\u2019s ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the investigational once-daily tablet grazoprevir\/elbasvir (100mg\/50mg) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6). 1 Patients in both the HCV infected, treatment-na\u00efve ( C-EDGE TN ), and HIV\/HCV co-infected, treatment-na\u00efve ( C-EDGE CO-INFXN ) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299\/316 and 207\/218, respectively). In addition, HCV infected, treatment-experienced patients ( C-EDGE TE ) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98\/104) and 92 percent (97\/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103\/106) and 92<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745212","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of data from the company\u2019s ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the investigational once-daily tablet grazoprevir\/elbasvir (100mg\/50mg) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6). 1 Patients in both the HCV infected, treatment-na\u00efve ( C-EDGE TN ), and HIV\/HCV co-infected, treatment-na\u00efve ( C-EDGE CO-INFXN ) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299\/316 and 207\/218, respectively). In addition, HCV infected, treatment-experienced patients ( C-EDGE TE ) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98\/104) and 92 percent (97\/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103\/106) and 92\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\\\/\",\"name\":\"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\\\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-23T00:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\\\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of data from the company\u2019s ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the investigational once-daily tablet grazoprevir\/elbasvir (100mg\/50mg) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6). 1 Patients in both the HCV infected, treatment-na\u00efve ( C-EDGE TN ), and HIV\/HCV co-infected, treatment-na\u00efve ( C-EDGE CO-INFXN ) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299\/316 and 207\/218, respectively). In addition, HCV infected, treatment-experienced patients ( C-EDGE TE ) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98\/104) and 92 percent (97\/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103\/106) and 92","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/","name":"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-23T00:00:00+00:00","dateModified":"2025-11-07T06:25:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevir-elbasvir-shows-high-sustained-virologic-responses-across-broad-range-of-patients-with-chronic-hepatitis-c-virus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir\/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a5a57071-7ee0-4407-871e-b63ba225f463","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Pivotal-Phase-3-C-EDGE-Program-Evaluating-GrazoprevirElbasvir-Shows-High-Sustained-Virologic-Responses-Across-Broad-Range-of-P-SHYH1.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745212\/revisions"}],"predecessor-version":[{"id":3674651,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745212\/revisions\/3674651"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745212"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}